Cyclerion Therapeutics, Inc.
CYCN
$3.00
-$0.01-0.33%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | 1.03M | 875.00K | 93.00K | 81.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | 1.03M | 875.00K | 93.00K | 81.00K |
| Cost of Revenue | 730.00K | 519.00K | 348.00K | 56.00K | 36.00K |
| Gross Profit | -730.00K | 506.00K | 527.00K | 37.00K | 45.00K |
| SG&A Expenses | 2.48M | 1.34M | 1.53M | 1.71M | 1.50M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.21M | 1.86M | 1.88M | 1.77M | 1.54M |
| Operating Income | -3.21M | -838.00K | -1.01M | -1.67M | -1.46M |
| Income Before Tax | -3.18M | -799.00K | -976.00K | -324.00K | -1.43M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -3.18M | -799.00K | -976.00K | -324.00K | -1.43M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -3.18M | -799.00K | -976.00K | -324.00K | -1.43M |
| EBIT | -3.21M | -838.00K | -1.01M | -1.67M | -1.46M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -0.76 | -0.21 | -0.30 | -0.11 | -0.56 |
| Normalized Basic EPS | -0.47 | -0.13 | -0.19 | -0.33 | -0.35 |
| EPS Diluted | -1.52 | -0.21 | -0.30 | -0.11 | -0.56 |
| Normalized Diluted EPS | -0.47 | -0.13 | -0.19 | -0.33 | -0.35 |
| Average Basic Shares Outstanding | 4.21M | 3.81M | 3.23M | 3.07M | 2.56M |
| Average Diluted Shares Outstanding | 4.21M | 3.81M | 3.23M | 3.07M | 2.56M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |